학술논문
Galectin-9 in autoimmune hepatitis: Correlation between serum levels of galectin-9 and M2BPGi in patients with autoimmune hepatitis.
Document Type
Academic Journal
Author
Matsuoka N; Clinical Research Center, Nagasaki Medical Center, Nagasaki.; Department of Rheumatology, Fukushima Medical University, Fukushima.; Kozuru H; Clinical Research Center, Nagasaki Medical Center, Nagasaki.; Koga T; Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki.; Abiru S; Clinical Research Center, Nagasaki Medical Center, Nagasaki.; Yamasaki K; Clinical Research Center, Nagasaki Medical Center, Nagasaki.; Komori A; Clinical Research Center, Nagasaki Medical Center, Nagasaki.; Fujita Y; Department of Rheumatology, Fukushima Medical University, Fukushima.; Tenmoku J; Department of Rheumatology, Fukushima Medical University, Fukushima.; Asano T; Department of Rheumatology, Fukushima Medical University, Fukushima.; Sato S; Department of Rheumatology, Fukushima Medical University, Fukushima.; Suzuki E; Department of Rheumatology, Fukushima Medical University, Fukushima.; Furuya M; Department of Rheumatology, Fukushima Medical University, Fukushima.; Kobayashi H; Department of Rheumatology, Fukushima Medical University, Fukushima.; Watanabe H; Department of Rheumatology, Fukushima Medical University, Fukushima.; Naganuma A; National Hospital Organization, Takasaki Medical Center, Takasaki.; Yoshizawa K; National Hospital Organization, Shinsyu-Ueda Medical Center, Ueda, Nagano.; Shimada M; National Hospital Organization, Nagoya Medical Center, Nagoya, Aichi.; Ario K; National Hospital Organization, Ureshino Medical Center, Ureshino, Saga.; Yamashita H; National Hospital Organization, Okayama Medical Center, Okayama.; Kohno H; National Hospital Organization, Kure Medical Center, Kure.; Kaneyoshi T; National Hospital Organization, Fukuyama Medical Center, Fukuyama, Hiroshima.; Nakamura M; Department of Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki.; Furukawa H; Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba.; Takahashi A; Department of Gastroenterology, Fukushima Medical University, Fukushima, Japan.; Kawakami A; Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki.; Ohira H; Department of Gastroenterology, Fukushima Medical University, Fukushima, Japan.; Yatsuhashi H; Clinical Research Center, Nagasaki Medical Center, Nagasaki.; Migita K; Clinical Research Center, Nagasaki Medical Center, Nagasaki.; Department of Rheumatology, Fukushima Medical University, Fukushima.
Source
Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
Subject
Language
English
Abstract
Autoimmune hepatitis (AIH) is a disorder of unknown etiology in which immune-mediated liver damage progresses to cirrhosis or hepatocellular carcinoma (HCC). The mainstay therapy for AIH is steroids and other immunosuppressive treatments. Currently, there are no validated markers for monitoring immune-mediated hepatic inflammation. Galectin-9 has recently been identified as a potential biomarker in patients with chronic liver disease. The objective of this study was to determine whether Galectin-9 and other serum proteins are associated with active disease in AIH patients.We enrolled 77 Japanese patients with well-documented AIH who were identified from the National Hospital Organization-AIH-liver-network database, as well as 32 patients with chronic hepatitis C (CHC), 27 patients with SLE, and 17 healthy control subjects. Serum levels of galectin-9, and markers of liver injury were measured and compared between groups.Serum levels of galectin-9 were significantly higher in AIH patients than in CHC patients (13.8 ± 4.9 ng/mL vs 8.9 ± 3.0 ng/mL, P < .001) or healthy controls (13.8 ± 4.9 ng/mL vs 5.0 ± 1.3 ng/mL, P < .001). In AIH group, serum galectin-9 levels weakly correlated with alanine aminotransferase levels or total bilirubin (TB) and strongly correlated with C-X-C motif chemokine 10 (CXCL10) and Mac-2 binding protein glycosylation isomer (M2BPGi) levels, but did not correlate with the histological grade of liver fibrosis. Steroid treatment of AIH patients significantly reduced serum galectin-9 levels (14.1 ± 4.9 ng/mL vs 8.3 ± 3.8 ng/mL, P < .001). SLE patients exhibited higher galectin-9 levels, whereas the galectin-9 levels did not correlate with liver function tests such as alanine aminotransferase levels.Serum galectin-9 correlated with disease status in AIH patients and could thus be useful biomarkers to detect hepatic autoimmunity. Because circulating galectin-9 reflects autoimmune-mediated inflammation, it may have additional utility as a biomarker for other autoimmune disorders.